1,720,962 research outputs found
sj-docx-5-taw-10.1177_20420986231213713 – Supplemental material for Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey
No full textSupplemental material, sj-docx-5-taw-10.1177_20420986231213713 for Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey by Yodit Fitsum, Azania Werede, Abubeker Mahmud Saleh, Eyasu H. Tesfamariam, Francis Magombo, Freminatos Misghina, Hermella Yemane, Iyassu Bahta, Liya Abraham, Merhawi Bahta, Merhawi Debesai, Meron Tesfagaber, Michael Ghirmai, Sirak Tesfamariam and Mulugeta Russom in Therapeutic Advances in Drug Safety</p
sj-docx-4-taw-10.1177_20420986231213713 – Supplemental material for Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey
No full textSupplemental material, sj-docx-4-taw-10.1177_20420986231213713 for Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey by Yodit Fitsum, Azania Werede, Abubeker Mahmud Saleh, Eyasu H. Tesfamariam, Francis Magombo, Freminatos Misghina, Hermella Yemane, Iyassu Bahta, Liya Abraham, Merhawi Bahta, Merhawi Debesai, Meron Tesfagaber, Michael Ghirmai, Sirak Tesfamariam and Mulugeta Russom in Therapeutic Advances in Drug Safety</p
sj-docx-2-taw-10.1177_20420986231213713 – Supplemental material for Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey
No full textSupplemental material, sj-docx-2-taw-10.1177_20420986231213713 for Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey by Yodit Fitsum, Azania Werede, Abubeker Mahmud Saleh, Eyasu H. Tesfamariam, Francis Magombo, Freminatos Misghina, Hermella Yemane, Iyassu Bahta, Liya Abraham, Merhawi Bahta, Merhawi Debesai, Meron Tesfagaber, Michael Ghirmai, Sirak Tesfamariam and Mulugeta Russom in Therapeutic Advances in Drug Safety</p
sj-docx-1-taw-10.1177_20420986231213713 – Supplemental material for Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey
No full textSupplemental material, sj-docx-1-taw-10.1177_20420986231213713 for Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey by Yodit Fitsum, Azania Werede, Abubeker Mahmud Saleh, Eyasu H. Tesfamariam, Francis Magombo, Freminatos Misghina, Hermella Yemane, Iyassu Bahta, Liya Abraham, Merhawi Bahta, Merhawi Debesai, Meron Tesfagaber, Michael Ghirmai, Sirak Tesfamariam and Mulugeta Russom in Therapeutic Advances in Drug Safety</p
sj-docx-3-taw-10.1177_20420986231213713 – Supplemental material for Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey
No full textSupplemental material, sj-docx-3-taw-10.1177_20420986231213713 for Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey by Yodit Fitsum, Azania Werede, Abubeker Mahmud Saleh, Eyasu H. Tesfamariam, Francis Magombo, Freminatos Misghina, Hermella Yemane, Iyassu Bahta, Liya Abraham, Merhawi Bahta, Merhawi Debesai, Meron Tesfagaber, Michael Ghirmai, Sirak Tesfamariam and Mulugeta Russom in Therapeutic Advances in Drug Safety</p
Praziquantel and risk of visual disorders: Case series assessment.
No full textIntroductionPraziquantel has been in use by helminthiasis and schistosomiasis control programs for about 30 years. Although deemed to be safe with regard to its adverse drug reaction profile in reference to the product information of Biltricide, the Eritrean Pharmacovigilance Center received reports of visual abnormalities related to the drug. This is a case series assessment of unusual cases of visual abnormalities associated with praziquantel.MethodsSearch was made in VigiBase by setting praziquantel as a drug substance, Eritrea as the reporting country and all eye disorders, high level term (HLT) to capture all visual disorders associated with Praziquantel. The retrieved dataset was exported into an Excel spreadsheet for descriptive analysis and causality was assessed using Austin Bradford-Hill criteria.ResultsThere are a total of 2579 Individual Case Safety Reports (ICSRs) of various Adverse Drug Reactions (ADRs) of praziquantel reported from Eritrea in VigiBase. The 61 reports of visual abnormalities that arose within the first 24 hours of praziquantel administration are of note. With a strong association as evidenced by the positive IC025 value, the association of praziquantel and blurred vision was consistently reported from different health facilities over a period of three years. It is a specific association in terms of both the exposure (only praziquantel) and the outcome (blurred vision) as reported in majority of the cases. However, experimental evidences for the association are lacking, the underweight profile of the Eritrean population suggests overdosing as a possible risk factor for the occurrence of these reactions.ConclusionThe strength, temporal plausibility, consistency and specificity of the association are suggestive of a causal association between praziquantel and visual disorders
Summary of selected variables for the 61 cases of visual abnormalities related to praziquantel (PZQ).
No full textSummary of selected variables for the 61 cases of visual abnormalities related to praziquantel (PZQ).</p
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Summary results of Praziquantel related cases of visual abnormalities submitted from Eritrea to the WHO global individual case safety reports database.
No full textSummary results of Praziquantel related cases of visual abnormalities submitted from Eritrea to the WHO global individual case safety reports database.</p
- …
